New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency
Botulinum neurotoxins (BoNTs) are notorious toxins and powerful agents and can be lethal, causing botulism, but they are also widely used as therapeutics, particularly to treat neuromuscular disorders. As of today, the commercial BoNT treatments available are from native A or B serotypes. Serotype F...
Main Authors: | David Burgin, Cindy Périer, Gavin Hackett, Mark Elliott, Daniel Kwan, Fraser Hornby, Imran Mir, Jacquie Maignel, Sai Man Liu, Matthew Beard |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/13/12/834 |
Similar Items
-
Recombinant botulinum neurotoxin serotype A1 in vivo characterization
by: Cindy Périer, et al.
Published: (2021-10-01) -
Comparison of botulinum neurotoxin type A formulations in Asia
by: Frevert J, et al.
Published: (2018-07-01) -
BoNT/A in the Urinary Bladder—More to the Story than Silencing of Cholinergic Nerves
by: Hodan Ibrahim, et al.
Published: (2022-01-01) -
Botulinum Neurotoxin A4 Has a 1000-Fold Reduced Potency Due to Three Single Amino Acid Alterations in the Protein Receptor Binding Domain
by: William H. Tepp, et al.
Published: (2023-03-01) -
Botulinum neurotoxin X lacks potency in mice and in human neurons
by: Brieana M. Gregg, et al.
Published: (2024-03-01)